Valuation: Evofem Biosciences, Inc.

Market Cap 9L 8L 8L 7L 13.12L 8.8Cr 13.33L 91.87L 36.02L 4.59Cr 34.82L 34.08L 15Cr P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 5.53Cr 4.92Cr 4.56Cr 4.15Cr 7.83Cr 525.26Cr 7.95Cr 55Cr 21Cr 274.1Cr 21Cr 20Cr 873.8Cr EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 week-11.39%
Current month-5.41%
1 month-11.39%
3 months-6.67%
6 months-21.35%
Current year-26.32%
1 week 0.01
Extreme 0.006
0.01
1 month 0.01
Extreme 0.006
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.23
5 years 0
Extreme 0.0008
1,378.12
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-11.39%-36.36%-92.22% 9L
+0.18%+6.47%+53.23%+103.61% 1,11600Cr
+0.78%-2.39%+32.82%+61.99% 61TCr
+0.72%+3.05%+25.58%+93.50% 50TCr
+1.01%+0.60%+74.54%+40.65% 36TCr
-0.13%+5.98%+32.91%+50.39% 37TCr
-0.95%+4.70%+19.51%+43.00% 29TCr
-1.98%+3.73%-0.86%+13.43% 26TCr
-0.30%+4.21%+46.16%+50.71% 23TCr
-1.04%+2.99%+32.11%+96.58% 20TCr
Average -0.21%+3.60%+27.96%+46.16% 39.3TCr
Weighted average by Cap. +0.06%+4.93%+39.05%+71.22%

Financials

2024 2025
Net sales 1.94Cr 1.72Cr 1.6Cr 1.45Cr 2.74Cr 183.77Cr 2.78Cr 19Cr 7.52Cr 96Cr 7.27Cr 7.11Cr 305.71Cr 2.02Cr 1.79Cr 1.66Cr 1.51Cr 2.85Cr 191.55Cr 2.9Cr 20Cr 7.84Cr 100Cr 7.57Cr 7.41Cr 318.66Cr
Net income -88.6L -78.76L -73L -66.41L -1.25Cr -84Cr -1.27Cr -8.77Cr -3.44Cr -44Cr -3.33Cr -3.25Cr -139.88Cr 4L 3L 3L 3L 6L 3.71Cr 6L 38.72L 15.18L 1.94Cr 14.67L 14.36L 6.17Cr
Net Debt 4.58Cr 4.07Cr 3.78Cr 3.44Cr 6.48Cr 435.06Cr 6.59Cr 45Cr 18Cr 227.03Cr 17Cr 17Cr 723.74Cr 5.44Cr 4.84Cr 4.48Cr 4.08Cr 7.7Cr 516.46Cr 7.82Cr 54Cr 21Cr 269.51Cr 20Cr 20Cr 859.15Cr
Projected Income Statement - Annual - Evofem Biosciences, Inc.
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
16/26/16 $0.007000 0.00% 51,135
15/26/15 $0.007000 +16.67% 2,75,875
14/26/14 $0.006000 -14.29% 8,09,632
13/26/13 $0.007000 -6.67% 34,284
12/26/12 $0.007500 -5.06% 62,507

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Evofem Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. EVFM Stock